Crossmark

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer

Crossref DOI link: https://doi.org/10.1007/s11864-018-0535-z

Published Online: 2018-03-12

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Strobl, Stephanie

Wimmer, Kerstin

Exner, Ruth

Devyatko, Yelena

Bolliger, Michael

Fitzal, Florian

Gnant, Michael
License Information

Text and Data Mining valid from 2018-03-12
More Information

Article History

First Online: 12 March 2018

Compliance with Ethical Standards

:

: Stephanie Strobl declares that she has no conflict of interest. Kerstin Wimmer has received a congress fee from Pfizer. Ruth Exner declares that she has no conflict of interest. Yelena Devyatko declares that she has no conflict of interest. Michael Bolliger declares that he has no conflict of interest. Florian Fitzal has received financial support for meetings from Novartis, Roche, Pfizer, and AstraZeneca, and has received honoraria from Roche and Pfizer. Michael Gnant has received research support through grants from AstraZeneca, Roche, Novartis, and Pfizer; and has received compensation from AstraZeneca, Roche, Novartis, Pfizer, Accelsiors, Amgen, Celgene, and OBI Pharma for service as a consultant.

: This article does not contain any studies with human or animal subjects performed by any of the authors.